A detailed history of Jacobs Levy Equity Management, Inc transactions in Alector, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,017,687 shares of ALEC stock, worth $5 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,017,687
Previous 858,576 18.53%
Holding current value
$5 Million
Previous $3.9 Million 21.94%
% of portfolio
0.02%
Previous 0.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.34 - $6.58 $690,541 - $1.05 Million
159,111 Added 18.53%
1,017,687 $4.75 Million
Q2 2024

Aug 14, 2024

SELL
$4.19 - $6.23 $269,094 - $400,109
-64,223 Reduced 6.96%
858,576 $3.9 Million
Q1 2024

May 15, 2024

BUY
$5.69 - $8.08 $731,250 - $1.04 Million
128,515 Added 16.18%
922,799 $5.56 Million
Q4 2023

Feb 14, 2024

BUY
$3.77 - $8.39 $61,100 - $135,976
16,207 Added 2.08%
794,284 $6.34 Million
Q3 2023

Nov 16, 2023

BUY
$5.2 - $8.77 $1.02 Million - $1.71 Million
195,411 Added 33.54%
778,077 $5.04 Million
Q2 2023

Aug 14, 2023

BUY
$5.86 - $7.93 $902,264 - $1.22 Million
153,970 Added 35.92%
582,666 $3.5 Million
Q1 2023

May 15, 2023

BUY
$5.85 - $9.84 $1.25 Million - $2.11 Million
214,095 Added 99.76%
428,696 $2.65 Million
Q4 2022

Feb 14, 2023

BUY
$6.88 - $9.55 $62,821 - $87,201
9,131 Added 4.44%
214,601 $1.98 Million
Q3 2022

Nov 15, 2022

BUY
$8.19 - $13.2 $1.68 Million - $2.71 Million
205,470 New
205,470 $1.94 Million
Q3 2020

Nov 16, 2020

SELL
$10.54 - $24.96 $194,779 - $461,260
-18,480 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$21.87 - $33.11 $404,157 - $611,872
18,480 New
18,480 $452,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $405M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.